Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343364 | 1.00 | KMT2A (0.41) | KMT2AIRAK1TOP2APTGS1NPC1 | |
| SCHEMBL30613816 | 0.91 | KMT2A (0.41) | KMT2AIRAK1TOP2APTGS1ADORA3 | |
| SCHEMBL25343406 | 0.91 | KMT2A (0.41) | KMT2AIRAK1TOP2APTGS1ADORA3 | |
| Hydrochloric Acid SCHEMBL25429470 | 0.90 | KMT2A (0.40) | KMT2AIRAK1TOP2APTGS1ADORA3 | |
| SCHEMBL27013395 | 0.81 | LMNA (0.49) | KMT2A | |
| SCHEMBL27013447 | 0.81 | KMT2A (0.47) | KMT2A | |
| SCHEMBL27013389 | 0.81 | KDM4E (0.43) | KMT2ANPC1RAB9ANR1H2NR1H3 | |
| SCHEMBL25343082 | 0.80 | KMT2A (0.36) | KMT2AIRAK1IRAK4 | |
| SCHEMBL30613749 | 0.80 | KMT2A (0.36) | KMT2AIRAK1IRAK4 | |
| SCHEMBL30613800 | 0.78 | MTNR1A (0.43) | KMT2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516064-B2 | Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD | SpringWorks Therapeutics Inc. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018148-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | KMT2A 2446/4885IRAK1 2701/4885TOP2A 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.